{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-036114","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.994751+00:00","generated_at":"2026-06-26T21:22:23.417281+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M","bullets":["Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).","Q4 net loss $8.6M vs $7.8M; FY net loss $33.3M vs $28.8M.","Gross margin improved to 68% in Q4; full-year 64%.","Cash $43.9M at Dec 31, 2021.","FY2022 revenue guidance $40-$45M; preliminary Q1 2022 revenue ~$8.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-036114","json":"https://secwatch.observer/filing/0001104659-22-036114.json","markdown":"https://secwatch.observer/filing/0001104659-22-036114.md","text":"https://secwatch.observer/filing/0001104659-22-036114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/0001104659-22-036114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/tm229728d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:22:23.417281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}